Skip to Main Content

Paper Details

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
Cancer Immunol Res
49
2022
-reactive TILs, Autologous, HLA, HLA-A*02-restricted TCR, Human, Solid Tumors, T, T-cell, T-cell Receptor-Engineered T Cells, T-cell receptors, TCR, TCRs, TIL, TP53, TP53 mutations, Tumor-Infiltrating Lymphocytes, autologous, autologous peripheral blood lymphocytes, autologous tumor-infiltrating lymphocytes, cancer, cancers, chemorefractory breast cancer, epithelial cancers, human, human leucocyte antigen, infused cells, metastatic solid cancers, mutant p53, mutant p53-reactive TILs, p53 Neoantigens, p53 neoantigens, p53R175H, patient, patients, solid tumors, tumor, tumor cells, tumor-infiltrating lymphocytes
Author NameAffiliation
Zhiya YuCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Zhiya YuCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Jared J GartnerCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Jared J GartnerCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Satyajit RayCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Satyajit RayCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Todd D PrickettCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Todd D PrickettCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Cuong Hoang-VuNational Cancer Institute, CCR and The Clinical Center
Steven A RosenbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
Steven A RosenbergCenter for Cancer Research, National Cancer Institute, National Institutes of Health
  • 1 - 11

Datasets

Release 1.2